Efficacy and safety of the glucagon receptor antagonist PF‐06291874: A 12‐week, randomized, dose‐response study in patients with type 2 diabetes mellitus on background metformin therapy

2018 ◽  
Vol 20 (11) ◽  
pp. 2608-2616 ◽  
Author(s):  
David J. Kazierad ◽  
Kristin Chidsey ◽  
Veena R. Somayaji ◽  
Arthur J. Bergman ◽  
Roberto A. Calle
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Receptor Antagonist ◽  
Dose Response ◽  
Efficacy And Safety ◽  
Glucagon Receptor ◽  
Glucagon Receptor Antagonist ◽  
Dose Response Study

Glucagon Receptor Antagonist LGD-6972 Significantly Lowers HbA1c and Is Well Tolerated after 12-Week Treatment in Patients with Type 2 Diabetes Mellitus (T2DM) on Metformin

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 73-OR ◽  
Author(s):  
JEREMY PETTUS ◽  
ERIC G. VAJDA ◽  
JAMES PIPKIN ◽  
GRETCHEN WILLIAMSON ◽  
MIRIAM A. ZANGMEISTER ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Receptor Antagonist ◽  
Glucagon Receptor ◽  
Glucagon Receptor Antagonist
Sign in / Sign up

Export Citation Format

Share Document